EXTON, Pa., May 13 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Seventh Annual JMP Securities Research Conference at 5:00 P.M. ET on Monday, May 19, 2008. The conference is being held at the Ritz-Carlton San Francisco.
ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com and available through May 30, 2008.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx).
ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV) and Clostridium difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com.
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved